Castle Biosciences, Inc. (CSTL)

Market Cap	706.75M
Revenue (ttm)	123.74M
Net Income (ttm)	-52.95M
Shares Out	26.35M
EPS (ttm)	-2.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	115,130
Open	27.00
Previous Close	26.71
Day's Range	25.95 - 27.10
52-Week Range	15.58 - 48.40
Beta	1.00
Analysts	Buy
Price Target	50.49 (+88.26%)
Earnings Date	Feb 27, 2023

About CSTL

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 25, 2019
• Employees: 517
• Stock Exchange: NASDAQ
• Ticker Symbol: CSTL

Financial Performance

In 2021, CSTL's revenue was $94.09 million, an increase of 50.18% compared to the previous year's $62.65 million. Losses were -$31.29 million, 204.3% more than in 2020.

Analyst Forecast

According to 14 analysts, the average rating for CSTL stock is "Buy." The 12-month stock price forecast is $50.49, which is an increase of 88.26% from the latest price.

Price Target

$50.49

(88.26% upside)

Analyst Consensus: Buy